This Phase 1/2, open-label, dose-finding study is intended to evaluate the safety and tolerability, PK, PD, and efficacy of INCB000928 administered as monotherapy or in combination with ruxolitinib in participants with MF who are transfusion-dependent or presenting with symptomatic anemia. This study will consist of 2 parts: dose escalation and expansion.
|Condition||Anemia, Post-essential Thrombocythemia Myelofibrosis, Post-polycythemia Vera Myelofibrosis|
|Clinical Study Identifier||NCT04455841|
|Last Modified on||22 October 2022|
You have contacted , on
Your message has been sent to the study team at ,
You are contacting
No annotations made yet
Congrats! You have your own personal workspace now.